5 / 10
Volume 8
Journal of Clinical & Experimental Pathology
ISSN : 2161-0681
Euro Pathology 2018 | Hematologic Oncology 2018
June 20-21, 2018
Page 26
Notes:
conference
series
.com
15
th
EUROPEAN PATHOLOGY CONGRESS
&
LEUKEMIA AND HEMATOLOGIC ONCOLOGY
June 20-21, 2018 | Paris, France
14
th
International Conference on
JOINT EVENT
Roberto Castelli, J Clin Exp Pathol 2018, Volume 8
DOI: 10.4172/2161-0681-C1-044
Personalized treatment strategies for elderly patients with myelodysplastic syndromes
M
yelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic disorders characterized by ineffective
hematopoiesis and peripheral cytopenia and their possible transformation into acute myeloid leukemia (AML). They
typically affect the elderly but when making treatment decisions, considering chronological age may be insufficient because
it poorly correlates with patient frailty. The challenge is to select the optimal treatment in these patients by balancing efficacy
and toxicity. We will discuss the rationale for and methods of personalizing the treatment of elderly MDS patients. Decisions
concerning treatment strategies for elderly MDS patients should be made after assessing their frailty on the basis of a geriatric
assessment and an estimation of age-adjusted life expectancy. We suggest that all elderly MDS patients should undergo a timed
up and go test (TUGT) as a preliminary means of identifying frail patients and that all non-frail patients should then undergo a
comprehensive geriatric assessment (CGA) in order to distinguish fit and pre-frail patients. Fit patients should receive standard
dose treatment, pre-frail patients should receive individualized therapy and frail patients should receive symptom-related
therapy. A repeated CGA may be useful to evaluate the hematological, cognitive and socio-relational effects of MDS treatment.
Biography
Roberto Castelli has obtained his degree in Medicine from University of Milan and then specialization in Internal Medicine and Hematology from University of Milan.
In addition, he obtained PhD in Clinical Methodology from University of Milan. He worked as Hematologist at Ospedale Maggiore di Milano University of Milan and at
University Hospital Ospedale Luigi Sacco. He is involved in malignant and non-malignant hematological disease focusing on myelodysplastic syndromes, acute and
chronic leukemias and myeloproliferative neoplasms. He is responsible of Leukemia Section at Ospedale Luigi Sacco University of Milan.
roberto.castelli@unimi.itRoberto Castelli
University of Milan, Italy